News & Updates
Filter by Specialty:
Zero HIV infections: Lenacapavir fulfils PURPOSE in cis women
In the interim analysis of the pivotal phase III PURPOSE 1 trial, twice-yearly subcutaneous lenacapavir, a first-in-class, high-potency HIV-1 capsid inhibitor, shows 100-percent efficacy and superiority to background HIV (bHIV*) incidence and daily oral emtricitabine/tenofovir disoproxil fumarate (F/TDF**) for pre-exposure prophylaxis (PrEP) in HIV-negative cisgender women.
Zero HIV infections: Lenacapavir fulfils PURPOSE in cis women
12 Aug 2024
Score model predicts prognosis in older adults with pneumonia
A new prediction score model identifies older patients with community-onset pneumonia who are nearing the end of life and need advance care planning (ACP) practices, reports a study.
Score model predicts prognosis in older adults with pneumonia
10 Aug 2024
Dolutegravir plus lamivudine suppresses HIV without HBV reactivation
The two-drug regimen dolutegravir plus lamivudine (DTG/3TC) is as good as 3- or 4-drug antiretroviral therapy (ART) regimens at keeping viral load suppressed while helping avoid hepatitis B virus (HBV) reactivation in people living with HIV-1 who have past exposure to HBV but no immunity, according to a post hoc analysis of five phase 3/3b studies.
